Literature DB >> 9352846

Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma.

Y Romero1, A J Cameron, G R Locke, D J Schaid, J M Slezak, C D Branch, L J Melton.   

Abstract

BACKGROUND & AIMS: Barrett's esophagus and adenocarcinoma are complications of gastroesophageal reflux disease. The aim of this study was to look for evidence of a familial predisposition to reflux.
METHODS: Index patients with adenocarcinoma (n = 27), Barrett's esophagus (n = 40), and reflux esophagitis (n = 55) were recruited from tertiary care and community populations. Parents and siblings of patients (n = 243) and their spouses' relatives (n = 230) completed reflux symptom questionnaires (response rate, 86%).
RESULTS: Reflux symptoms were significantly more prevalent among parents and siblings of patients with adenocarcinoma (43% vs. 23%) and Barrett's esophagus (46% vs. 27%) than spouse control relatives. No significant difference was found for the reflux esophagitis group (33% vs. 29%). Reflux was more prevalent in siblings than spouses of patients with Barrett's esophagus (41% vs. 12%) and adenocarcinoma (40% vs. 6%), a difference that was not found with reflux esophagitis (24% vs. 32%). Reflux was associated with obesity, 41% vs. 28% in the nonobese; smoking, 45% vs. 31% in nonsmokers; and men, 39% vs. 27% in women.
CONCLUSIONS: There may be a genetic predisposition to the development of reflux in families of patients with Barrett's esophagus and esophageal adenocarcinoma. For uncomplicated reflux esophagitis, environmental factors appear more important.

Entities:  

Mesh:

Year:  1997        PMID: 9352846     DOI: 10.1053/gast.1997.v113.pm9352846

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  40 in total

1.  No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

2.  The pathogenesis of Barrett's esophagus: a process in continuum or discontinuum.

Authors:  R C Fitzgerald; M J Farthing
Journal:  Curr Gastroenterol Rep       Date:  2000-12

3.  Spouse controls in family case-control studies: a methodological consideration.

Authors:  Bas A J Verhage; Katja K H Aben; Huub Straatman; André L M Verbeek; Terri H Beaty; Lambertus A Kiemeney
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

4.  Genetic influences in gastro-oesophageal reflux disease: a twin study.

Authors:  I Mohammed; L F Cherkas; S A Riley; T D Spector; N J Trudgill
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

5.  Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  C M Drovdlic; K A B Goddard; A Chak; W Brock; L Chessler; J F King; J Richter; G W Falk; D K Johnston; J L Fisher; W M Grady; S Lemeshow; C Eng
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

6.  Familial association in barrett esophagus.

Authors:  Yvonne Romero
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-05

Review 7.  Barrett esophagus: an update.

Authors:  Rami J Badreddine; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 46.802

8.  Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: pro.

Authors:  Tomás Navarro-Rodriguez; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

9.  Personal and family history of cancer and the risk of Barrett's esophagus in men.

Authors:  N Khalaf; D Ramsey; J R Kramer; H B El-Serag
Journal:  Dis Esophagus       Date:  2014-02-17       Impact factor: 3.429

10.  Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults.

Authors:  A Chak; T Lee; M F Kinnard; W Brock; A Faulx; J Willis; G S Cooper; M V Sivak; K A B Goddard
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.